US 12,239,822 B2
Portable drug mixing and delivery device and associated methods
Brent Buchine, Austin, TX (US); Adam R. Standley, Cambridge, MA (US); Christopher J. Stepanian, Somerville, MA (US); Kaliappanadar Nellaiappan, Watertown, MA (US); Cole Constantineau, Cambridge, MA (US); Michel Bruehwiler, Newton, MA (US); Jeffrey Thomas Chagnon, Bow, NH (US); and Robert Brik, Cambridge, MA (US)
Filed by Windgap Medical, Inc., Watertown, MA (US)
Filed on Nov. 5, 2019, as Appl. No. 16/675,219.
Application 16/675,219 is a continuation in part of application No. 16/423,344, filed on May 28, 2019.
Application 16/423,344 is a continuation in part of application No. 15/832,346, filed on Dec. 5, 2017, granted, now 10,300,198, issued on May 28, 2019.
Application 15/832,346 is a continuation in part of application No. 15/034,967, granted, now 9,907,911, issued on Mar. 16, 2018, previously published as PCT/US2015/045761, filed on Aug. 18, 2015.
Application 16/675,219 is a continuation in part of application No. 16/266,341, filed on Feb. 4, 2019, abandoned.
Application 16/266,341 is a continuation in part of application No. 14/255,909, filed on Apr. 17, 2014, granted, now 10,195,361, issued on Feb. 5, 2019.
Application 14/255,909 is a continuation in part of application No. 14/218,355, filed on Mar. 18, 2014, granted, now 9,199,037, issued on Dec. 1, 2015.
Application 16/675,219 is a continuation in part of application No. 14/975,695, filed on Dec. 18, 2015, granted, now 11,246,842.
Application 16/675,219 is a continuation in part of application No. 14/576,179, filed on Dec. 18, 2014, abandoned.
Claims priority of provisional application 62/204,940, filed on Aug. 13, 2015.
Claims priority of provisional application 62/126,011, filed on Feb. 27, 2015.
Claims priority of provisional application 62/120,792, filed on Feb. 25, 2015.
Claims priority of provisional application 62/061,664, filed on Oct. 8, 2014.
Claims priority of provisional application 62/038,386, filed on Aug. 18, 2014.
Claims priority of provisional application 61/917,943, filed on Dec. 19, 2013.
Claims priority of provisional application 61/800,014, filed on Mar. 15, 2013.
Claims priority of provisional application 62/094,063, filed on Dec. 18, 2014.
Claims priority of provisional application 62/016,260, filed on Jun. 24, 2014.
Claims priority of provisional application 62/756,056, filed on Nov. 5, 2018.
Claims priority of provisional application 61/917,925, filed on Dec. 18, 2013.
Prior Publication US 2020/0139048 A1, May 7, 2020
Int. Cl. A61M 5/24 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/4045 (2006.01); A61K 38/26 (2006.01); A61K 45/06 (2006.01); A61M 5/14 (2006.01); A61M 5/19 (2006.01); A61M 5/20 (2006.01); A61M 5/28 (2006.01); A61M 5/32 (2006.01); A61M 5/44 (2006.01); A61K 38/00 (2006.01)
CPC A61M 5/2448 (2013.01) [A61K 9/0019 (2013.01); A61K 31/137 (2013.01); A61K 31/4045 (2013.01); A61K 38/26 (2013.01); A61K 45/06 (2013.01); A61M 5/1409 (2013.01); A61M 5/19 (2013.01); A61M 5/2046 (2013.01); A61M 5/284 (2013.01); A61M 5/3294 (2013.01); A61M 5/44 (2013.01); A61K 38/00 (2013.01); A61M 2205/364 (2013.01); A61M 2205/366 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A dual chamber drug mixing system comprising:
a housing;
a first chamber and a second chamber disposed at least partially within the housing, the first chamber axially aligned with the second chamber, wherein the first chamber has an outlet, the outlet of the first chamber offset from a central longitudinal axis of the housing, and the second chamber has an inlet and wherein the first chamber and the second chamber are not in communication during a closed state;
a first medicament component provided in the first chamber;
a second medicament component provided outside the first chamber, the second medicament component including an opioid antagonist compound in the amount of 1 mg/kg to 25 mg/kg based on a recipient's weight;
a user operable mixing system having a first displacement mechanism, wherein when the user operable mixing system is activated, fluidic communication occurs between the outlet of the first chamber and the inlet of the second chamber and the first displacement mechanism within the first chamber drives the first medicament component into the second chamber; and
a valve disposed between the outlet of the first chamber and the inlet of the second chamber, wherein the valve is configured to open or close a fluidic pathway between the first chamber and the second chamber,
wherein the first chamber and the second chamber are configured to move within the housing independently with respect to each other, as the first chamber has a first sidewall and the second chamber has a second sidewall separate and distinct from the first sidewall.